Multinational KD Pharma has acquired a new British manufacturing site that will expand their base for production of active pharmaceutical precursors for the omega-3 market, especially substances customized to a buyer's need. "Multiple technologies exist for fractionating lipids that operate off of different chemistry principles, so having a wider technology portfolio allows us to find the most efficient path to isolate specific fatty acids, like EPA and DHA, based on the characteristics of the raw material coming in and the finished product we want to make," said Adam Ismail, chief strategy officer.
Omega-3 ingredient supplier focuses on tailored chemistry
Sign up for Inform SmartBrief
Global fats and oils news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.